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cientiﬁc Comment
ational neonatal screening program for
emoglobinopathies: how far have we advanced?ilvana Fahel da Fonseca ∗
niversidade de Brasília (UnB), Brasília, DF, Brazilhanks to the efforts of Dr. Robert Guthrie at the beginning
f the sixties, neonatal screening has become a true diagnos-
ic tool for diseases that, if not detected early, can result in
mportant complications to the health of the child.1 Today,
eonatal screening represents one of themain advances in the
revention of pediatric diseases, and is based on diagnosing
athologies that are relatively frequent and severe, that can be
etected by methods that are simple, efﬁcient and adaptable
o large-scale application, and that can be treated to substan-
ially modify the course of the disease.2
In Brazil, neonatal screening was ﬁrst initiated by profes-
or Benjamin Schmidt in 1976, but for a long time, there was
o investment in or commitment to the treatment and follow-
p of screened children.3,4 After 2001, the Ministry of Health,
hrough the Bill #822/GM, instituted the National Neonatal
creening Program (NNSP)5 in the public healthcare system,
ncorporating the principles of neonatal screening: universal
ccess to early diagnosis, and intervention in the disease with
he use of therapies and interdisciplinary care, mandating
hierarchy of responsibilities and competencies at the fed-
ral, state and municipal levels. Sickle cell disease and other
emoglobinopathies were included in the NNSP,5 allowing the
doption of prophylactic measures and complete treatment of
hildren with these diseases before the development of clini-
al complications, thereby having an impact on morbidity and
6–12ortality.
Screening should be considered a public health service
ith universal access and monitoring of screened individuals.
DOI of original article: http://dx.doi.org/10.1016/j.bjhh.2014.05.001.
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eserved.The NNSP was essential to increase the screening coverage in
Brazil,3 but the higher number of screened children is only
one of the indicators of the efﬁciency of such a program. Rules
and regulations for all steps of screening are necessary, as is
the production of informative material for patients and pro-
fessionals, training of professionals, and especially, critical
evaluation of the program, based on the results over the long
term.13
Soares et al.14 and other researchers,15–17 on reporting
their data, demonstrate the challenges faced by a neonatal
screening program in a country of continental dimensions,
especially in regions and populations with social and eco-
nomic problems. Pechansky and Thomas in 198118 developed
parameters for access to medical care, and some of these were
later analyzed by Botler3 in relation to neonatal screening pro-
grams. The data from Soares et al.14 highlight one of these:
accessibility, deﬁned as the relationship between the location
of the service and the location of the users, taking into account
the resources necessary to permit the user to avail from the
services.
The data reported by Soares et al., 14 together with those
from previous studies,19–21 as well as the indicators recorded
in the NNSP management system, can help to deﬁne new care
strategies for Brazilian children with hemoglobinopathies.
The training and certiﬁcation of pediatricians of governmentersitário Darcy Ribeiro, Asa Norte, 70910-900 Brasília, DF, Brazil.
health clinics to treat these patients in their residential
areas, greater integration of the Family Health Program
with the NNSP, investment in infrastructure to allow greater
e Terapia Celular. Published by Elsevier Editora Ltda. All rights
oter.
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local independence, and a greater involvement of professional
societies3 all need to be discussed. Some of the data presented
by Soares et al.,14 such as absence of family planning and
indifference to early care for a second affected child, reinforce
the importance of investment in information sources for
families.
The foundation stone was put into place a half a century
ago by Guthrie, now we need to identify and tear down the
barriers that stand in the way of more effective results of the
NNSP for the patient, the family, and society.
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